{"entity":{"id":"dirk-schadendorf","kind":"person","name":"Dirk Schadendorf","aka":[],"tldr":"Melanoma expert who directs the West German Cancer Center at University Hospital Essen.","summary":"Dirk Schadendorf is Director of the West German Cancer Center (WTZ) and Director of the Department of Dermatology at University Hospital Essen. He is one of Europe's most prolific melanoma investigators, having led or co-led pivotal trials of immune checkpoint inhibitors and BRAF/MEK-targeted therapy in adjuvant and metastatic settings. Under his leadership the WTZ is a designated German comprehensive cancer centre and part of the NCT West network.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://wtz-essen.de/direktorium-wtz-essen/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Schadendorf+D%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","melanoma","immunotherapy"],"related":[],"cancers":["melanoma","cutaneous-scc","merkel-cell-carcinoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["essen-wtz"],"pathways":[],"terms":[],"trials":["checkmate-067"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director WTZ Essen; Director, Department of Dermatology","institutionId":"essen-wtz","specialisms":["Melanoma","Skin cancer","Immunotherapy and targeted therapy"],"profiles":[{"label":"Institution profile","url":"https://wtz-essen.de/direktorium-wtz-essen/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Schadendorf+D%5BAuthor%5D"}],"papers":[{"title":"Melanoma","journal":"Lancet","year":2018,"url":"https://doi.org/10.1016/S0140-6736(18)31559-9","doi":"10.1016/S0140-6736(18)31559-9"},{"title":"Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716)","journal":"Lancet","year":2022,"url":"https://doi.org/10.1016/S0140-6736(22)00562-1","doi":"10.1016/S0140-6736(22)00562-1"},{"title":"Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma (IMMUNED)","journal":"Lancet","year":2020,"url":"https://doi.org/10.1016/S0140-6736(20)30417-7","doi":"10.1016/S0140-6736(20)30417-7"}]},"route":"/people/dirk-schadendorf/","neighbours":{"cancer":[{"id":"cutaneous-scc","kind":"cancer","name":"Cutaneous squamous cell carcinoma","route":"/cancers/cutaneous-scc/"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"merkel-cell-carcinoma","kind":"cancer","name":"Merkel cell carcinoma","route":"/cancers/merkel-cell-carcinoma/"}],"institution":[{"id":"essen-wtz","kind":"institution","name":"West German Cancer Center (WTZ), University Hospital Essen","route":"/institutions/essen-wtz/"}],"trial":[{"id":"checkmate-067","kind":"trial","name":"CheckMate 067","route":"/trials/checkmate-067/"}]}}